Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025

Core Insights - Soleno Therapeutics, Inc. is presenting data on Prader-Willi syndrome (PWS) and its clinical program for VYKAT™ XR at the ISPOR Meeting 2025 [1][2] - VYKAT XR is approved for treating hyperphagia in patients with PWS aged 4 years and older [4][9] Group 1: Presentation Details - The first presentation focuses on mortality rates from a Phase 3 clinical trial of patients with hyperphagia and PWS treated with VYKAT XR, scheduled for May 14 [2] - The second presentation examines the burden of PWS on patients and the healthcare system, highlighting emergency department visits and inpatient stays, scheduled for May 15 [2] Group 2: About Prader-Willi Syndrome - PWS occurs in approximately 1 in 15,000 live births, characterized by hyperphagia, which can severely impact quality of life [3] - Additional symptoms include behavioral issues, cognitive disabilities, low muscle tone, and increased risk of serious health complications [3] Group 3: About VYKAT XR - VYKAT XR was approved by the FDA on March 26, 2025, and is now available for U.S. patients [4] - It is a once-daily oral treatment specifically for hyperphagia in individuals with PWS [9]